A study on the level of serum neopterin a new novel biomarker in acute myocardial infarction

Introduction: Acute myocardial infarction (AMI) is one of the most common diseases, and it is one of the important medical emergencies admitted in the hospitals. It is characterized by the presence of clinical features like sudden onset of severe chest pain with dysponea, palpitation and profuse sweating leading to cardiac arrythmias, cardiogenic shock, cardiac failure and death if not treated early(2). Among the biomarkers for diagnosis and prognosis in AMI, the Neopterin, a pteridine derivative is considered to be one of the new novel bio-markers which is found to be elevated in patients with AMI. Neopterin was first isolated from larvae of bee in 1963(3). Eventually Neopterin was identified as the fluorescent component that was elevated in the urine of mice with Ehrlich ascites tumor (4). Estimation of Serum levels of Neopterin is a new novel biomarker in AMI and seems to be a prognostic marker for MACE in AMI. Aim: To elucidate the role of Neopterin levels and its short term prognostic significance in AMI. Methods: Neopterin is an activation marker for monocytes / macrophages and its circulating levels in the Serum is considered to be one of the prognostic markers in the treatment of AMI.